Loading...
•
Jun 30, 2022
Paysign Q2 2022 Earnings Report
Paysign's financial performance improved with increased revenue, improved margins, and onboarding of a record number of new plasma donation centers.
Key Takeaways
Paysign reported strong Q2 2022 results with improvements in top and bottom lines and gross margins. The company onboarded a record number of new plasma donation centers and expects revenue to grow 27.5% over 2021.
Improved top and bottom lines.
Increased gross margins.
Onboarded a record number of new plasma donation centers.
Expects revenue to grow 27.5% over 2021.
Paysign
Paysign
Forward Guidance
Paysign anticipates continued revenue growth, driven primarily by its plasma business, with total revenue expected to grow 27.5% over 2021. Full-year gross profit margins are expected to be between 56% and 57%. Adjusted EBITDA is expected to be $4.7 million to $5.3 million.
Positive Outlook
- Total revenue to grow 27.5% over 2021.
- Plasma is estimated to make up about 92% of total revenues for 2022.
- Full-year gross profit margins are expected to be between 56% and 57%.
- Q3 2022 total revenues to be approximately $10.2 million.
- Q4 2022 total revenues to be approximately $10.5 million.
Challenges Ahead
- Two pharma prepaid programs ending in mid-November.
- Operating expenses expected to be approximately $22.0 million.
- Q3 2022 Adjusted EBITDA being slightly higher than Q4 2022 due to the end of the pharma prepaid programs.
- Labor shortages at plasma donation centers.
- Restrictions preventing Mexican nationals with tourist visas from being compensated for donating plasma.